Patent application number | Description | Published |
20090298881 | Water-Soluble Artemisinin Derivatives, Their Preparation Methods, the Pharmaceutical Compositions and the Use Thereof - Water-soluble artemisinin derivatives, their preparation methods, the pharmaceutical compositions containing the same derivatives and the use thereof are disclosed. The artemisinin derivatives have following formula I. It has been proved by pharmacological tests that these compounds and compositions have evident immuno-suppressive activities, and may be used in the preparation of novel immuno-suppressants for treating the diseases caused by hyperfunction of human immunity (e.g. the auto-immune diseases such as lupus erythematosus, rheumatoid arthritis, multiple sclerosis and the like), and for inhibiting the graft rejection after cell or organ transplantation. | 12-03-2009 |
20100056569 | Heterocyclic Non-Nucleoside Compounds, Their Preparation, Pharmaceutical Composition And Their Use As Antiviral Agents - The invention relates a kind of antiviral agents, more concretely, relates to a kind of heterocyclic non-nucleoside compounds with the following structures, their preparation and pharmaceutical compositions including the compounds. The said compounds can be used as antiviral agents and as medicaments for treating diseases such as hepatitis B, influenza, herpes, HIV and so on. | 03-04-2010 |
20110201810 | Method for Preparing 4-[9-(6-Aminopurine)]-2-(S)-Hydroxyl-Butyric Acid Methyl Ester - The present invention discloses a novel method for preparing and purifying 4-(6-Amino-purin-9-yl)-2(S)-hydroxy-butyric acid methyl ester. The preparation started from cheap and easily available L-malic acid, which was transformed to intermediate I after simultaneous protection of the groups of 1-carboxyl and 2-hydroxyl. The intermediate I was selectively reduced to intermediate alcohol II, whose hydroxyl group was further transformed to an easily leaving group to afford intermediate III. The intermediate III was nucleophilically substituted with adenine to afford intermediate IV. The intermediate IV was deprotected and methyl-esterified simultaneously in methanol in the presence of an acid or a base to afford crude 4-(6-Amino-purin-9-yl)-2(S)-hydroxy-butyric acid methyl ester, which was purified by recrystallization to afford the purified product. Comparing with the prior preparation methods, the present method has advantages in low cost, mild conditions, high retention of the chiral center during the reaction, high productivity, great improvement in the quality and yield of the product and great decrease in cost, and thus is suitable for the production on a large scale. | 08-18-2011 |
20120136687 | System and Method for CAPA Process Automation - The present disclosure involves systems, products, and methods for automatically generating a CAPA plan. One method includes operations for identifying an issue associated with a business system; identifying a set of information associated with the issue including a plurality of evaluation factors defining the issue; identifying a set of weighting values associated with the issue, each weighting values associated with a particular evaluation factor; evaluating the issue based on the plurality of evaluation factors combined with the corresponding weighting value, determining at least one root cause for the issue based on the evaluation results, identifying at least one corrective or preventive action based at least in part on the at least one determined root cause for the issue, and automatically generating the CAPA plan including the at least one determined root cause and the at least one identified corrective or preventive action associated with the issue. | 05-31-2012 |
20130059895 | 2',2-DITHIAZOL NON-NUCLEOSIDE COMPOUNDS, PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS AND USES AS HEPATITIS VIRUS INHIBITORS THEREOF - The present disclosure belongs to the field of pharmaceutical chemistry, and relates to a class of 2′,2-bisthiazole non-nucleoside compounds of following formula I, the preparation method and the pharmaceutical composition thereof. The compounds have both the anti-HBV and anti-HCV activities and are useful in treating hepatitides B and C. Pharmacokinetic tests showed the compounds have good bioavailability. | 03-07-2013 |
20130261139 | USE OF A QUINAZOLINE COMPOUND IN PREPARING A MEDICAMENT AGAINST FLAVIVIRIDAE VIRUS - Disclosed is a use of a quinazoline compound of Formula I having 2,4-diaminoquinazoline as a parent nucleus in preparation of a medicament for treating diseases caused by flaviviridae infection, especially a use in combating Hepatitis C virus infection and Dengue fever virus infection. | 10-03-2013 |
20140379919 | APPLYING A PLATFORM CODE LEVEL UPDATE TO AN OPERATIONAL NODE - Provided are a computer program product, system, and method for applying a platform code level update to update a source partition in a computing system. Computational resources in the computing system are allocated to a destination partition. A code load is applied to the destination partition to implement an updated platform code level comprising an update to the platform code level on the source partition while the source partition is operational and processing computing requests. Submission of new transactions to the source partition is blocked in response to applying the code load to the destination partition. An operational environment and system state at the source partition are migrated to the destination partition in response to blocking submission of new transactions to the source partition. Transactions are directed to the destination partition intended for the source partition in response to migrating the operational environment and system state to the destination partition. | 12-25-2014 |
20150268946 | MANAGING A CODE LOAD - A method and system for managing a code load for a storage system is disclosed. The method and system can include instantiating a code load. The code load can include a first update for a first component and a second update for a second component. The method and system can include monitoring the operational state of the first and second components in response to instantiating the code load. The method and system can also include determining to perform the first update in response to a triggering event. The method and system can also include performing the first update in response to determining to perform the first update. | 09-24-2015 |